News

Meeting Report – Cell manufacture is key

Sunday 6 November 2016
Country
United Kingdom

If the cell therapy industry were a housing project, then arguably it would be at the construction stage – deciding what materials are needed to make a safe and durable product. Manufacture is a key issue for the industry, but one that is just now being confronted, according to participants at a meeting of the Alliance for Regenerative Medicine that took place in London on 3 November.

Genmab raises its 2016 guidance

Thursday 3 November 2016
Country
Denmark

Genmab A/S has raised its guidance for 2016 while announcing strong nine-month revenue, raising expectations that its partnered anticancer drug, Darzalex (daratumumab), will generate serious income in the future. The drug has received two breakthrough designations from the FDA.. 

Device for stroke prevention

Thursday 3 November 2016
Country
United States

The Food and Drug Administration has approved a new device for closing small holes in the heart called patent foramen ovales (PFO), which in some patients can be a cause of recurrent strokes. The non-surgical device can be inserted through a catheter in a vein in the leg.

Lundbeck posts favourable results, raises guidance

Wednesday 2 November 2016
Country
Denmark

H. Lundbeck A/S, the Danish pharmaceutical company specialising in psychiatric and neurological disorders, has raised its guidance for 2016 following a larger-than-expected increases in sales and earnings so far this year. 

Analysis: The financial impact of Shire’s acquisition of Baxalta

Wednesday 2 November 2016
Country
Ireland

Third-quarter results from Shire Plc give a further insight into the financial impact of its acquisition of Baxalta Inc – the company’s biggest acquisition to date. The $32 billion deal, completed on 3 June, comes on the heels of two other multi-billion dollar deals in 2015.

Promethera raises €10 million for cell therapies

Tuesday 1 November 2016
Country
Belgium

Belgium-based Promethera Biosciences SA, which is developing cell-based treatments for in-born errors of metabolism and acquired liver disease, has raised €10 million in a Series C-extension financing to expand its portfolio.

Transgene aims to raise €48 million for vaccines

Tuesday 1 November 2016
Country
France

Transgene SA aims to raise about €48 million in a rights issue and private placement in order to finance the clinical development of its cancer vaccines, three of which will be investigated in combination with immune checkpoint inhibitors.

Money for Spanish venture capital firm

Monday 31 October 2016
Country
Spain

Barcelona, Spain-based Ysios Capital has raised €126.4 million for a new fund that will invest in biotechnology, medical device and diagnostic companies across Europe, with a special emphasis on Spain. Ysios BioFund II Innvierte is expected to finance up to 15 early-stage companies.

Ablynx prepares vobarilizumab for Phase 3

Monday 31 October 2016
Country
Belgium

Ablynx NV is poised to consult regulatory authorities in the US and Europe on plans for the Phase 3 development of its biologic for rheumatoid arthritis vobarilizumab. The Belgium-based company will also initiate discussions with potential partners for the drug.

Novo Nordisk to diversify away from diabetes

Monday 31 October 2016
Country
Denmark

Novo Nordisk A/S plans to become a diversified pharmaceutical company instead of relying mostly on its large diabetes franchise, for which it claims a 27% global market share.